Search

Your search keyword '"Rolla, V.C."' showing total 4 results
Start Over Author "Rolla, V.C."
4 results on '"Rolla, V.C."'

1. Determinants of losses in the tuberculosis infection cascade of care among children and adolescent contacts of pulmonary tuberculosis cases: A Brazilian multi-centre longitudinal study

Author

Sobral, L., Arriaga, Maria B., Souza, A.B., Araújo-Pereira, M., Barreto-Duarte, B., Sales, C., Rocha, M.S., Benjamin, A., Moreira, A.S.R., de Oliveira, J.G., Carvalho, A.C., Spener-Gomes, R., Figueiredo, M.C., Cavalcante, S., Durovni, B., Lapa-e-Silva, J.R., Kritski, A.L., Rolla, V.C., Sterling, T.R., Cordeiro-Santos, M., Andrade, B.B., and RePORT Brazil consortium

Subjects
Pediatric, Latent tuberculosis, Health Policy, Contact, Public Health, Environmental and Occupational Health, Internal Medicine, Children, TBI cascade
Abstract

Background: Approximately 10% of the global tuberculosis (TB) burden is in children. Identification, diagnosis, and early treatment of Mycobacterium tuberculosis infection (TBI) is critical to prevent progression to TB in children. The risk of TB, including severe disease, is highest in children

Published
2022

2. Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis

Author

Arriaga, Maria B., Karim, F., Queiroz, A.T.L., Araújo-Pereira, M., Barreto-Duarte, B., Sales, C., Moosa, M.-Y.S., Mazibuko, M., Milne, G.L., Maruri, F., Serezani, C.H., Koethe, J.R., Figueiredo, M.C., Kritski, A.L., Cordeiro-Santos, M., Rolla, V.C., Sterling, T.R., Leslie, A., and Andrade, B.B.

Subjects
dysglycemia, urinary eicosanoids, Mycobacterium tuberculosis, lipid mediators, anti-tuberculosis treatment
Abstract

Background: Oxidized lipid mediators such as eicosanoids play a central role in the inflammatory response associated with tuberculosis (TB) pathogenesis. Diabetes mellitus (DM) leads to marked changes in lipid mediators in persons with TB. However, the associations between diabetes-related changes in lipid mediators and clearance of M. tuberculosis (Mtb) among persons on anti-TB treatment (ATT) are unknown. Quantification of urinary eicosanoid metabolites can provide insights into the circulating lipid mediators involved in Mtb immune responses. Methods: We conducted a multi-site prospective observational study among adults with drug-sensitive pulmonary TB and controls without active TB; both groups had sub-groups with or without dysglycemia at baseline. Participants were enrolled from RePORT-Brazil (Salvador site) and RePORT-South Africa (Durban site) and stratified according to TB status and baseline glycated hemoglobin levels: a) TB-dysglycemia (n=69); b) TB-normoglycemia (n=64); c) non-TB/dysglycemia (n=31); d) non-TB/non-dysglycemia (n=29). We evaluated the following urinary eicosanoid metabolites: 11α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (major urinary metabolite of prostaglandin E2, PGE-M), tetranor-PGE1 (metabolite of PGE2, TN-E), 9α-hydroxy-11,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (metabolite of PGD2, PGD-M), 11-dehydro-thromboxane B2 (11dTxB2), 2,3-dinor-6-keto-PGF1α (prostaglandin I metabolite, PGI-M), and leukotriene E4 (LTE4). Comparisons between the study groups were performed at three time points: before ATT and 2 and 6 months after initiating therapy. Results: PGE-M and LTE4 values were consistently higher at all three time-points in the TB-dysglycemia group compared to the other groups (p

Published
2022

3. Poor response to tuberculosis treatment with regimens without rifampicin in immunosuppressed AIDS patients

Author

O'Donnel M.M., Souza Carvalho S., Gadelha A.J., Morgado M.G., Galhardo M.C.G., Lourenço M.C., and Rolla V.C.

Subjects
AIDS, immunosuppression, rifampicin, tuberculosis, Infectious and parasitic diseases, RC109-216, Microbiology, QR1-502
Abstract

A prospective study was conducted on 79 advanced immunosuppressed AIDS patients from 1997 to 1999, during which nine cases of tuberculosis (TB) were diagnosed. The main clinical and laboratory characteristics and the response to TB treatment were reviewed. The clinical manifestations of TB were: pulmonary (six cases), extrapulmonary (two cases) and disseminated (one case). These patients were being treated with highly active antiretroviral treatment (HAART) and were not responding. In three cases an optional regimen without rifampicin (RMP) was indicated to maintain HAART during TB treatment. A clinical response to TB treatment (disappearance of fever) was observed in 6/9 patients during a mean of 73 days (SD = 96). The three unresponsive patients were those treated without RMP. A switch to TB regimens containing RMP was proposed and successful. In our study, though it was limited by a small sample size, the response to TB regimens without rifampin was poor in immunossupressed patients failing HAART.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results